Cryopreserved ampule of Normal Human Atrial Cardiac Fibroblasts (NHCF-A) containing ≥ 500,000 cells
Cryopreserved ampule of Normal Human Ventricular Cardiac Fibroblasts (NHCF-V) containing ≥ 500,000 cells
The medium-throughput module for the 4D-Nucleofector® Platform suited for transfection of hard-to-transfect cell lines or primary cells in 96-well format
For efficient transfection of cell lines, e.g. HepG2, HL-60, Jurkat, K-562 , MCF7, SH-SY5Y, or THP-1, in the NucleofectorTM I/II/2b System
Do you need a quote right away? Add this product to your shopping cart, go to your cart and click on “Generate Quote”. Your quote will be available straight away to view, save online, and download in PDF format.
Cryopreserved ampule of Human Lung Microvascular Endothelial Cells (HMVEC-L) containing ≥ 500,000 cells
-
References - X-Vivo™Overview of relevant references
-
Primary Normal Human Cells and MediaIn Vivo Relevance. In Vitro Results. Updated and revised cell content.
-
X-VIVO Reference Guide 2025A curated list of peer-reviewed articles related to X-VIVO RUO media as used for culturing different primary cells and is a resource for potential consumers to find scientific data.
-
Building Better In Vitro Models Using the Quasi Vivo® SystemOverview webinar providing details and application data using the Quasi Vivo® Systems delivered by Dr. Kelly Davidge, Scientist at Kirkstall Inc. -
Terms and Conditions TheraPEAK® T-VIVO® Sample Request ProgramTerms and Conditions TheraPEAK® T-VIVO® Sample Requests
-
Instructions for Use – TheraPEAK® X-VIVO® Cell Culture MediumInstructions for how to use the X-VIVO® Media Series
-
TheraPEAK® T-VIVO® Cell Culture Medium – OverviewView or download this document for a comprehensive overview and learn how the chemically defined TheraPEAK® T-VIVO® Medium enhances T-cell culture and accelerates therapy development.
-
TheraPEAK® X-VIVO® Hematopoietic Cell Culture MediumSerum-free, GMP produced medium for cell therapy applications
-
Non-viral Gene Modification for Ex-vivo Cell TherapyIn this interview our Director Transfection R&D discusses the advantages of non-viral transfection technologies for CRISPR- or transposon-based genetic modification cell and gene therapy.
-
A Novel In Vitro Liver Cell Culture Flow System Allowing Long-Term Metabolism and Hepatotoxicity Studies]Manuscript published in Applied In Vitro Toxicology journal describes improvement of CYP450 phenotype of primary cryopreserved hepatocytes using Quasi Vivo® System